• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    4D Molecular Therapeutics Inc (NQ: FDMT )

    8.120 -0.160 (-1.93%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about 4D Molecular Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
    Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation 
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
    4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... 
    Via Benzinga
    4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    The Latest Analyst Ratings For 4D Molecular Therapeutics
    Via Benzinga
    Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
    Via Benzinga
    Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
    Via Benzinga
    Analyst Expectations For 4D Molecular Therapeutics's Future
    Via Benzinga
    Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    4DMT Announces Presentations at Upcoming Retina Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in the 2024 Cantor Global Healthcare Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024
    FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
    4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing... 
    Via Benzinga
    4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
    Via Benzinga
    Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
    4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.